• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

6,154
2,053
1,977
1,631
1,448

COUNTRY

1,008
796
248
216
175

CATEGORIES

  • 943
  • 190
  • 125
  • 327
    • 55
  • 471
  • 233
  • 264
  • 65
  • 79
  • 814
  • 1,445
  • 855
  • 24
  • 460
  • 1,370
  • 2,267
    • 89
    • 129
    • 72
    • 72
    • 43
    • 43
    • 21
    • 17
    • 20
    • 22
  • 25
  • 273
  • 49

PRICE

5,280
10,591
20,023
26,193

PUBLISHED

3,696
5,195
10,214
26,193

PRODUCT TYPE

22,083
1,956
1,009
893
164
37
21
19
6
4
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) -...

July 2014
FROM

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast...

July 2014
FROM

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast...

July 2014
FROM

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast...

July 2014
FROM

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast...

July 2014
FROM

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Anacetrapib (Acute Coronary Syndrome) -...

July 2014
FROM

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast...

July 2014
FROM

Adaptive Licensing - A Holistic Approach to Drug Development and Regulation

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of...

July 2014
FROM

Pediatric Drug Development - Regulatory Challenges and Commercial Opportunities

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric...

July 2014
FROM

Glaucoma - Pipeline Review, H2 2014

Glaucoma - Pipeline Review, H2 2014 Summary This, ‘Glaucoma - Pipeline Review, H2 2014’, provides an overview of the Glaucoma’s therapeutic pipeline. This report provides comprehensive information...

July 2014
FROM

Small-Cell Lung Cancer - Pipeline Review, H2 2014

Small-Cell Lung Cancer - Pipeline Review, H2 2014 Summary This, ‘Small-Cell Lung Cancer - Pipeline Review, H2 2014’, provides an overview of the Small-Cell Lung Cancer’s therapeutic pipeline. This...

July 2014
FROM

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Exceptionally Large and Innovative Pipeline: The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms...

July 2014
FROM

Chronic Bronchitis - Pipeline Review, H2 2014

Chronic Bronchitis - Pipeline Review, H2 2014 Summary This, ‘Chronic Bronchitis - Pipeline Review, H2 2014’, provides an overview of the Chronic Bronchitis’s therapeutic pipeline. This report provides...

July 2014
FROM

PharmaPoint: Acute Coronary Syndrome - Current and Future Players

PharmaPoint: Acute Coronary Syndrome - Current and Future Players Summary The publisher has released its pharma report, “PharmaPoint: Acute Coronary Syndrome - Current and Future Players”. The report...

July 2014
FROM
IMS Country Review 2014: India IMS Country Review 2014: India - Product Thumbnail Image

IMS Country Review 2014: India

IMS Country Review™ 2014 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years Sales performance is analysed in terms...

July 2014
IMS Country Review 2014: Turkey IMS Country Review 2014: Turkey - Product Thumbnail Image

IMS Country Review 2014: Turkey

IMS Country Review™ 2014 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years Sales performance is analysed in terms...

July 2014
IMS Country Review 2014: Mexico IMS Country Review 2014: Mexico - Product Thumbnail Image

IMS Country Review 2014: Mexico

IMS Country Review™ 2014 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years Sales performance is analysed in terms...

July 2014
IMS Country Review 2014: Romania IMS Country Review 2014: Romania - Product Thumbnail Image

IMS Country Review 2014: Romania

IMS Country Review™ 2014 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years Sales performance is analysed in terms...

July 2014
Pharmaceuticals Wholesaling in Australia Pharmaceuticals Wholesaling in Australia - Product Thumbnail Image

Pharmaceuticals Wholesaling in Australia

Pharmaceuticals Wholesaling in Australia The industry comprises companies that wholesale human-use pharmaceutical products, including prescription drugs, over-the-counter medicines and complementary...

July 2014
FROM
IMS Country Review 2014: Poland IMS Country Review 2014: Poland - Product Thumbnail Image

IMS Country Review 2014: Poland

IMS Country Review™ 2014 provides comprehensive qualitative insights into a specific pharmaceutical market as well as showing sales trends over the last 5 years Sales performance is analysed in terms...

July 2014
Loading Indicator

Our Clients

Our clients' logos